JACOBS LEVY EQUITY MANAGEMENT, INC
Position in ACAD — Acadia Pharmaceuticals Inc
CIK 884414
FLORHAM PARK, NJ
Position in ACAD
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,948,790
-$228,068 QoQ
Shares Held
116,553
-18.3% QoQ
Ownership
0.068%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#97
of 354 holders
Holding Since
Mar 2021
19 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ACAD Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026JACOBS LEVY EQUITY MANAGEMENT, INC holds $740,535,030 across 80 Biotechnology names. ACAD ranks #37 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
256,503 | $159,939,880 | |
| 2 | RARE |
Ultragenyx Pharmaceutical Inc.
|
2,939,719 | $98,157,217 | |
| 3 | INCY |
Incyte Corp
|
731,774 | $82,953,900 | |
| 4 | CORT |
Corcept Therapeutics Inc
|
695,532 | $60,476,507 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
322,377 | $25,232,447 | |
| 6 | EXEL |
Exelixis, Inc.
|
415,650 | $22,615,516 | |
| 7 | AUPH |
Aurinia Pharmaceuticals Inc.
|
1,231,516 | $20,898,826 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
60,986 | $18,358,615 |
All Filings in ACAD
Export CSV
19 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,948,790 | 116,553 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $3,176,858 | 142,716 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $9,910,665 | 371,047 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $15,835,944 | 742,078 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $16,418,738 | 761,184 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $32,845,145 | 1,977,432 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $20,895,218 | 1,138,704 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $18,630,009 | 1,211,314 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $22,018,782 | 1,355,002 | Shares | Sole | 2024-08-14 | |
| 2023-12-31 | $3,299,948 | 105,396 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $29,684,558 | 1,424,403 | Shares | Sole | 2023-11-17 | |
| 2023-06-30 | $43,972,631 | 1,836,018 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $35,425,883 | 1,882,353 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $26,095,793 | 1,639,183 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $17,775,172 | 1,086,502 | Shares | Sole | 2022-11-15 | |
| 2022-03-31 | $14,283,163 | 589,726 | Shares | Sole | 2022-05-16 | |
| 2021-12-31 | $12,628,387 | 541,062 | Shares | Sole | 2022-02-14 | |
| 2021-09-30 | $8,474,887 | 510,228 | Shares | Sole | 2021-11-15 | |
| 2021-03-31 | $486,201 | 18,845 | Shares | Sole | 2021-05-17 | |
| No filing history on record for this holder in this stock. | ||||||